# A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT06163898** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 4 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Alnuctamab
- **DRUG:** Mezigdomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06163898
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-27
- **Primary completion:** 2025-06-03
- **Final completion:** 2025-06-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06163898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06163898, "A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06163898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*